Septerna (NASDAQ:SEPN) Stock Price Down 6.3% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN) shares fell 6.3% during trading on Monday . The stock traded as low as $26.26 and last traded at $26.2250. 134,506 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 189,530 shares. The stock had previously closed at $27.98.

Wall Street Analyst Weigh In

SEPN has been the subject of several research analyst reports. Wells Fargo & Company upgraded Septerna from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $18.00 to $28.00 in a research report on Friday, November 14th. Raymond James Financial began coverage on Septerna in a research note on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. Truist Financial started coverage on shares of Septerna in a research report on Monday, December 15th. They issued a “buy” rating and a $34.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Septerna from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Septerna Stock Down 4.3%

The firm has a fifty day moving average of $24.98 and a 200-day moving average of $18.25. The firm has a market cap of $1.20 billion, a P/E ratio of -17.74 and a beta of 3.85.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28). The firm had revenue of $21.50 million for the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%. Sell-side analysts anticipate that Septerna, Inc. will post -7.11 EPS for the current year.

Insider Buying and Selling

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the completion of the sale, the senior vice president owned 92,911 shares in the company, valued at approximately $1,677,972.66. The trade was a 3.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

Institutional investors have recently made changes to their positions in the stock. Nuveen LLC acquired a new position in Septerna in the first quarter valued at about $139,000. Woodline Partners LP boosted its stake in Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after acquiring an additional 282,585 shares during the last quarter. Rhumbline Advisers boosted its stake in Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after acquiring an additional 3,323 shares during the last quarter. Geode Capital Management LLC grew its holdings in Septerna by 19.1% during the second quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after purchasing an additional 78,316 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Septerna in the second quarter valued at approximately $129,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.